- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06112418
Randomizované srovnání personalizované péče založené na stadia onemocnění srdce versus obvyklá péče o prevenci příhod (TRANSFORM)
Randomizované srovnání personalizované péče na základě stadia ischemické choroby srdeční versus obvyklá péče o primární prevenci kardiovaskulárních příhod
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Cardiovascular disease (CVD) persists as the leading cause of morbidity and mortality worldwide at high societal cost. The current primary CVD prevention strategy relies upon risk stratification using population health markers such as age, sex, diabetes, hypertension, dyslipidemia and tobacco use, with preventive therapy intensified in higher risk strata. Since these risk factors are indirect surrogate markers of the underlying disease, atherosclerosis, this strategy leads to treatment of individuals with risk factors who do not have atherosclerosis and failure to treat those with significant atherosclerosis who lack risk factors. The current strategy also cannot determine which individuals are inadequately treated despite effective risk factor management (residual risk). With the current approach, the CV death rate is trending upward in the US despite evidence that screening asymptomatic patients reduces CV events and the widespread availability of effective preventive therapies.
This randomized, controlled, pragmatic trial is designed to address the unmet need for better strategies to identify asymptomatic individuals at increased risk for CV events due to atherosclerosis and to personalize their treatment based on CV risk estimates using coronary artery disease (CAD) visualization and quantification.
This study enrolls patients without known symptoms of ASCVD but who are at increased risk for ASCVD due to their age and having diabetes, prediabetes or metabolic syndrome and tests the hypothesis that a CAD Staging System-based care strategy reduces CV events compared with risk factor-based care. The Cleerly CAD Staging System incorporates imaging-based evaluation for coronary atherosclerosis, algorithm-supported pharmacotherapy and personalized education about their CAD.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Ryann Sardinia
- Telefonní číslo: 7207398191
- E-mail: ryann.sardinia@cleerlyhealth.com
Studijní záloha kontaktů
- Jméno: Ashley Dunham, PhD
- Telefonní číslo: 7207398191
- E-mail: ashley.dunham@cleerlyhealth.com
Studijní místa
-
-
Arizona
-
Chandler, Arizona, Spojené státy, 85224
- Nábor
- Chandler Clinical Trials
-
Kontakt:
- Muhammad Salim, MD
-
Scottsdale, Arizona, Spojené státy, 85260
- Nábor
- Scottsdale Clinical Trials
-
Kontakt:
- Todd Dreitzler, MD
-
Sun City, Arizona, Spojené státy, 85381
- Nábor
- Sun City Research
-
Kontakt:
- Juan Rodriguez, MD
-
Tucson, Arizona, Spojené státy, 85704
- Nábor
- Noble Clinical Research
-
Kontakt:
- Roxana Rodriguez, MD
-
-
California
-
Beverly Hills, California, Spojené státy, 90210
- Nábor
- Cardiovascular Research Foundation of Southern California
-
Kontakt:
- Ronald P. Karlsberg, MD
-
Beverly Hills, California, Spojené státy, 90211
- Nábor
- Amicis Research: Beverly Hills
-
Kontakt:
- Michael Levine, MD
-
Canoga Park, California, Spojené státy, 91303
- Nábor
- Valiance Clinical Research - Canoga Park
-
Kontakt:
- Rami Shaarawy
-
Chula Vista, California, Spojené státy, 91911
- Nábor
- Cardiovascular Institute of San Diego
-
Kontakt:
- Milind D. Parikh, MD
-
Granada Hills, California, Spojené státy, 91324
- Nábor
- Amicis Research: Granada Hills
-
Kontakt:
- Pascal Dabel, MD
-
Huntington Park, California, Spojené státy, 90255
- Nábor
- Valiance Clinical Research: Huntington Park
-
Kontakt:
- Philip Kim, MD
-
Indian Wells, California, Spojené státy, 92210
- Nábor
- HALO Diagnostics
-
Kontakt:
- John F. Feller, MD
-
La Jolla, California, Spojené státy, 92037
- Nábor
- Scripps Health
-
Kontakt:
- Elizabeth Epstein, MD
-
Lancaster, California, Spojené státy, 93534
- Nábor
- Chemidox Clinical Trials
-
Kontakt:
- Pamela Dewar-DeSilva, MD
-
Loma Linda, California, Spojené státy, 92354
- Nábor
- Loma Linda University Health
-
Kontakt:
- Purvi Parwani, MD
-
Long Beach, California, Spojené státy, 90805
- Nábor
- Long Beach Research Institute
-
Kontakt:
- Ashley Duzik, MD
-
Monterey Park, California, Spojené státy, 91754
- Nábor
- Ace Research Institute - Monterey Park
-
Kontakt:
- Yu-Hsiang Sam Lee, MD
-
Newhall, California, Spojené státy, 91321
- Nábor
- Amicis Research: Newhall
-
Kontakt:
- Thuong Vo, MD
-
Northridge, California, Spojené státy, 91324
- Nábor
- Ace Research Institute: Northridge
-
Kontakt:
- Richard Park, MD
-
Northridge, California, Spojené státy, 91324
- Nábor
- Amicis Research: Northridge
-
Kontakt:
- Nana Barseghian, MD
-
Northridge, California, Spojené státy, 91325
- Nábor
- Ace Research Institute: Northridge #2
-
Kontakt:
- William Y. Josephson, MD
-
Northridge, California, Spojené státy, 91325
- Aktivní, ne nábor
- Northridge Clinical Trials
-
Orange, California, Spojené státy, 92868
- Nábor
- University of California- Irvine
-
Kontakt:
- Ailin Barseghian El-Farra, MD
-
Palo Alto, California, Spojené státy, 94304
- Nábor
- Stanford Health Care
-
Kontakt:
- Sandra Tsai, MD
-
Palo Alto, California, Spojené státy, 94304
- Nábor
- VA Palo Alto
-
Kontakt:
- Shriram Nallamshetty, MD
-
San Fernando, California, Spojené státy, 91306
- Nábor
- Amicis Research: San Fernando
-
Kontakt:
- Farid Yasharpour, MD
-
Tarzana, California, Spojené státy, 91356
- Nábor
- Valiance Clinical Research - Tarzana
-
Kontakt:
- Harpreet Singh, MD
-
Torrance, California, Spojené státy, 90502
- Nábor
- Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
-
Kontakt:
- Suvasini Lakshmanan, MD
-
Valencia, California, Spojené státy, 91355
- Nábor
- Amicis Research: Valencia
-
Kontakt:
- Dennis Lewis, MD
-
Valley Village, California, Spojené státy, 91607
- Nábor
- Concierge Clinical Trials
-
Kontakt:
- Neal R. Cutler, MD
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- Nábor
- University of Colorado
-
Kontakt:
- Steve Simon
-
Vrchní vyšetřovatel:
- Steve Simon, MD
-
Denver, Colorado, Spojené státy, 80218
- Nábor
- St. Josephs (Intermountain Healthcare)
-
Kontakt:
- Christopher Angus, MD
-
-
Florida
-
Boca Raton, Florida, Spojené státy, 33434
- Nábor
- Flourish Medical Research
-
Kontakt:
- Michael Hafran, MD
-
Cross City, Florida, Spojené státy, 32628
- Nábor
- Apex Research
-
Kontakt:
- Tamir Salmani, MD
-
Hialeah, Florida, Spojené státy, 33012
- Nábor
- Evolution Research Center
-
Kontakt:
- Riquel Gonzalez, MD
-
Jacksonville, Florida, Spojené státy, 32209
- Nábor
- UF Health Jacksonville
-
Kontakt:
- Luis Ortega Paz, MD
-
Miami, Florida, Spojené státy, 33137
- Nábor
- BioPhase Research
-
Kontakt:
- Julie Cadet-Plassman, MD
-
Miami, Florida, Spojené státy, 33135
- Nábor
- Fiel Wellness Clinical Research LLC
-
Kontakt:
- Osvaldo Caroma, MD
-
Miami, Florida, Spojené státy, 33155
- Nábor
- United Clinical Research
-
Kontakt:
- Teresa B. Alfonso, MD
-
Kontakt:
- Alfonso
-
Miami, Florida, Spojené státy, 33173
- Nábor
- Atlantis Clinical Research, LLC
-
Kontakt:
- Leyvi Alvarado Miranda, MD
-
Miami, Florida, Spojené státy, 33183
- Nábor
- Farma Medical Inc.
-
Kontakt:
- Ingrid Fernandez-Milian, MD
-
Miami, Florida, Spojené státy, 33173
- Nábor
- Baptist Health Miami Cardiac and Vascular Institute
-
Kontakt:
- Jonathan Fialkow, MD
-
Miami, Florida, Spojené státy, 33186
- Nábor
- New Access Research and Medical Center
-
Kontakt:
- Sander Fernandez, MD
-
Miami Beach, Florida, Spojené státy, 33140
- Nábor
- Quantum Clinical Trials
-
Kontakt:
- Christopher A. Fayeghi, MD
-
Pensacola, Florida, Spojené státy, 32504
- Nábor
- Ascension Sacred Heart
-
Kontakt:
- Rohit Amin, MD
-
Pompano Beach, Florida, Spojené státy, 33060
- Nábor
- Clinical Research Center of Florida
-
Kontakt:
- Howard S. Koch, MD
-
Tampa, Florida, Spojené státy, 33620
- Nábor
- University of South Florida
-
Kontakt:
- Shone Almeida, MD
-
-
Georgia
-
Augusta, Georgia, Spojené státy, 30907
- Nábor
- Aiyan Diabetes Center
-
Kontakt:
- Anthony D. Turner, MD
-
Dunwoody, Georgia, Spojené státy, 30338
- Nábor
- Emory University
-
Kontakt:
- Ambar Kulshreshtha, MD
-
Fayetteville, Georgia, Spojené státy, 30214
- Nábor
- Privia Medical Group Georgia LLC -Fayetteville (Javara)
-
Kontakt:
- Charlotte Grayson Mathis, MD
-
Lithia Springs, Georgia, Spojené státy, 30122
- Nábor
- Randomize Now- Atlanta West
-
Kontakt:
- Millard Collier Jr., MD
-
Macon, Georgia, Spojené státy, 31210
- Nábor
- Randomize Now-Burton Medical
-
Kontakt:
- Frederick Burton, MD
-
Norcross, Georgia, Spojené státy, 30092
- Nábor
- Evergreen Clinical Trials
-
Kontakt:
- Dmitriy Pelishev, MD
-
Powder Springs, Georgia, Spojené státy, 30127
- Nábor
- Peachtree Clinical Solutions - Noir Research Collective
-
Kontakt:
- Karan Raghavan, MD
-
Riverdale, Georgia, Spojené státy, 30296
- Nábor
- Randomize Now, LLC - Noir Research Collective
-
Kontakt:
- Claire K. Willie, MD
-
Savannah, Georgia, Spojené státy, 31406
- Nábor
- Privia Medical Group Georgia, LLC (Javara Inc.)
-
Kontakt:
- Thomas G. Moriarity, MD
-
Thomasville, Georgia, Spojené státy, 31792
- Nábor
- Privia Medical Group Georgia - Thomasville (Javara)
-
Kontakt:
- William L. Cooper, MD
-
-
Idaho
-
Meridian, Idaho, Spojené státy, 83642
- Nábor
- Care Institute- High Desert
-
Kontakt:
- David A. Hinchman, MD
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Nábor
- Northwestern University
-
Kontakt:
- Paul C. Cremer, MD
-
Glenview, Illinois, Spojené státy, 60026
- Nábor
- Northshore University Health System
-
Kontakt:
- Amit K. Pursnani, MD
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46237
- Nábor
- Franciscan Physician Network- Indiana Heart Physicians
-
Kontakt:
- Ryan P Daly, MD
-
Indianapolis, Indiana, Spojené státy, 46202
- Nábor
- Indiana Medical Research Institute
-
Kontakt:
- Arshad P. Malik
-
-
Iowa
-
West Des Moines, Iowa, Spojené státy, 50266
- Nábor
- MercyOne Iowa Heart Center
-
Kontakt:
- Enrico L. Martin, MD
-
-
Kentucky
-
Edgewood, Kentucky, Spojené státy, 41017
- Nábor
- St Elizabeth Health Care - CRI
-
Kontakt:
- Erica Pivato, MD
-
Louisville, Kentucky, Spojené státy, 40202
- Nábor
- UofL Health
-
Kontakt:
- Shahab Ghafghazi, MD
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70127
- Nábor
- Ascension DePaul Services Research Center
-
Kontakt:
- Kristen Thomas, MD
-
-
Maryland
-
Bowie, Maryland, Spojené státy, 20715
- Nábor
- Flourish Bowie dba Flourish Research
-
Kontakt:
- Sara Collins, MD
-
Columbia, Maryland, Spojené státy, 21045
- Nábor
- KUR Research at CMP
-
Kontakt:
- William Saway, MD
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02115
- Nábor
- Brigham and Women's Hospital
-
Kontakt:
- Ron Blankstein, MD
-
Boston, Massachusetts, Spojené státy, 02114
- Nábor
- Massachusetts General Hospital
-
Kontakt:
- Pradeep Natarajan, MD
-
-
Michigan
-
Detroit, Michigan, Spojené státy, 48202
- Nábor
- Henry Ford Hospital
-
Kontakt:
- Cori E Russell, MD
-
Ypsilanti, Michigan, Spojené státy, 48917
- Nábor
- Trinity Health Michigan Heart
-
Kontakt:
- Ahmad Mizyed, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55407
- Nábor
- Minneapolis Heart Institute Foundation
-
Kontakt:
- Michael D. Miedema, MD
-
-
Missouri
-
St Louis, Missouri, Spojené státy, 63110
- Nábor
- Washington University School of Medicine
-
Kontakt:
- Farhan M. Katchi, MD
-
St Louis, Missouri, Spojené státy, 63136
- Nábor
- Saint Louis Heart and Vascular
-
Kontakt:
- Gil Vardi, MD
-
-
Montana
-
Kalispell, Montana, Spojené státy, 59901
- Nábor
- Boeson Research Kalispell
-
Kontakt:
- Justin Buls, MD
-
Missoula, Montana, Spojené státy, 59804
- Nábor
- Boeson Research Fort Missoula
-
Kontakt:
- Audrey Remmers, MD
-
-
Nebraska
-
Lincoln, Nebraska, Spojené státy, 68506
- Nábor
- Bryan Heart
-
Kontakt:
- Chad E. Travers, MD
-
-
Nevada
-
Las Vegas, Nevada, Spojené státy, 89128
- Nábor
- Vector Clinical Trials
-
Kontakt:
- Bharat R. Mocherla, MD
-
Las Vegas, Nevada, Spojené státy, 89102
- Nábor
- Southwest Medical Associates- Optum Nevada
-
Kontakt:
- Tatiana O. Tsvetkova, MD
-
-
New Jersey
-
Flemington, New Jersey, Spojené státy, 08822
- Nábor
- Advanced Heart and Vascular Institute of Hunterdon
-
Kontakt:
- Andrey Espinoza, MD
-
Marlton, New Jersey, Spojené státy, 08053
- Nábor
- Virtua Health, Inc.
-
Kontakt:
- Mark T. Finch, MD
-
New Brunswick, New Jersey, Spojené státy, 08901
- Nábor
- Rutgers State University
-
Kontakt:
- Sabahat Bokhari, MD
-
Paramus, New Jersey, Spojené státy, 07652
- Nábor
- The Valley Hospital
-
Kontakt:
- Himanshu Gupta, MD
-
Teaneck, New Jersey, Spojené státy, 07666
- Nábor
- Holy Name Medical Center
-
Kontakt:
- Jaffar Raza, MD
-
-
New York
-
Brooklyn, New York, Spojené státy, 11221
- Nábor
- Clindove Research
-
Kontakt:
- Nelly Cohen, MD
-
Brooklyn, New York, Spojené státy, 11226
- Nábor
- Swift Clinical Research
-
Kontakt:
- Manoj Dalmia, MD
-
Jackson Heights, New York, Spojené státy, 11372
- Nábor
- Rasaj Research
-
Kontakt:
- Ammara Mushtaq, MD
-
Lake Success, New York, Spojené státy, 11042
- Nábor
- Optum- Long Island NY
-
Kontakt:
- Steven Goldberg, MD
-
Mount Kisco, New York, Spojené státy, 10549
- Nábor
- Northwell Health Northern Westchester Hospital
-
Kontakt:
- Margaret Andersen, MD
-
New York, New York, Spojené státy, 10019
- Nábor
- Mount Sinai West
-
Kontakt:
- Waqas A Malick, MD
-
New York, New York, Spojené státy, 10029
- Nábor
- Mount Sinai
-
Kontakt:
- Solomon Bienstock, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27599
- Nábor
- University of North Carolina at Chapel Hill
-
Kontakt:
- Matthew Cavender, MD
-
Durham, North Carolina, Spojené státy, 27701
- Nábor
- Duke University Hospital
-
Kontakt:
- William Yancy, MD
-
Durham, North Carolina, Spojené státy, 27705
- Nábor
- Durham Veterans Affairs Medical Center (Durham VAMC)
-
Kontakt:
- Hayden Bosworth, MD
-
Fayetteville, North Carolina, Spojené státy, 28304
- Nábor
- Cape Fear Valley Health System (Javara Inc.)
-
Kontakt:
- Nafisa Saleem, MD
-
Morehead City, North Carolina, Spojené státy, 28557
- Aktivní, ne nábor
- West Clinical Research
-
Winston-Salem, North Carolina, Spojené státy, 27157
- Nábor
- Wake Forest University Health Sciences
-
Kontakt:
- Michael Shapiro, MD
-
-
North Dakota
-
Fargo, North Dakota, Spojené státy, 58102
- Nábor
- Sanford Health
-
Kontakt:
- David J. Clardy, MD
-
-
Ohio
-
Akron, Ohio, Spojené státy, 44304
- Nábor
- Summa Health
-
Kontakt:
- Wissam Alajaji, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73109
- Nábor
- Medical Research International, LLC
-
Kontakt:
- Joseph Grillo, MD
-
Oklahoma City, Oklahoma, Spojené státy, 73007
- Nábor
- Hightower Clinical
-
Kontakt:
- Faisal Latif, MD
-
Tulsa, Oklahoma, Spojené státy, 74104
- Nábor
- Ascension St. John - Jane Phillips Medical Center
-
Kontakt:
- Michael Megaly, MD
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Spojené státy, 17011
- Nábor
- Capital Area Research
-
Kontakt:
- Venkatesh Nadar, MD
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Nábor
- Medical University of South Carolina
-
Kontakt:
- Marc-Andre Cornier, MD
-
-
Tennessee
-
Cleveland, Tennessee, Spojené státy, 37312
- Nábor
- Community DPC
-
Kontakt:
- Carlton Volberg, MD
-
Knoxville, Tennessee, Spojené státy, 37920
- Nábor
- University of Tennessee Medical Center
-
Kontakt:
- Kashif A. Shaikh, MD
-
Nashville, Tennessee, Spojené státy, 37202
- Nábor
- TriStar Centennial Medical Center (HCA Health Care)
-
Kontakt:
- David Huneycutt, MD
-
-
Texas
-
Abilene, Texas, Spojené státy, 79601
- Nábor
- Hendrick Health
-
Kontakt:
- Ren Zhang, MD
-
Beaumont, Texas, Spojené státy, 77702
- Nábor
- Gadolin Research
-
Kontakt:
- John T Fowler, MD
-
Greenville, Texas, Spojené státy, 75402
- Nábor
- CardioVoyage, LLC
-
Kontakt:
- Marc Demyun, MD
-
Houston, Texas, Spojené státy, 77025
- Nábor
- Kelsey Research Foundation
-
Kontakt:
- Rohan R Wagle, MD
-
Houston, Texas, Spojené státy, 77004
- Nábor
- Helium Research Group
-
Kontakt:
- Ijeoma A. Ekeruo
-
Houston, Texas, Spojené státy, 77070
- Nábor
- Gulf Coast Clinical Research, LLC
-
Kontakt:
- Anjani Pandya, MD
-
Houston, Texas, Spojené státy, 77030
- Nábor
- The Methodist Hospital, DeBakey Cardiology Associates
-
Kontakt:
- Sadeer Al-Kindi, MD
-
Laredo, Texas, Spojené státy, 78041
- Nábor
- Aeres Clinical Research
-
Kontakt:
- Amando Garza, MD
-
Lewisville, Texas, Spojené státy, 75057
- Nábor
- DC Clinical Research
-
Kontakt:
- Moiz M. Shafiq, MD
-
McKinney, Texas, Spojené státy, 75069
- Nábor
- North Dallas Research Associates - Kerlo Network
-
Kontakt:
- Muhammad Akram Khan, MD
-
Mesquite, Texas, Spojené státy, 75149
- Nábor
- SMS Clinical Research
-
Kontakt:
- Salma Saiger, MD
-
San Marcos, Texas, Spojené státy, 78666
- Nábor
- Privia Medical Group Gulf Coast, PLLC ( Javara Inc.)
-
Kontakt:
- Alan Lee, MD
-
Stephenville, Texas, Spojené státy, 76401
- Nábor
- Privia Medical Group- North Texas
-
Kontakt:
- Benjamin Marcum, MD
-
-
Utah
-
West Valley City, Utah, Spojené státy, 84120
- Zatím nenabíráme
- Kalo Clinical Research
-
Kontakt:
- William J. Walsh, MD
-
-
Virginia
-
Richmond, Virginia, Spojené státy, 23225
- Nábor
- Chippenham Johnston Willis Medical Center
-
Kontakt:
- Michael Arcarese, MD
-
-
Washington
-
Everett, Washington, Spojené státy, 98201
- Nábor
- Providence Regional Medical Center Everett
-
Kontakt:
- Xiaojing Jennie Shen, MD
-
Seattle, Washington, Spojené státy, 98195
- Nábor
- University of Washington
-
Kontakt:
- Kelley Branch, MD
-
-
West Virginia
-
Charleston, West Virginia, Spojené státy, 25304
- Nábor
- Charleston Area Medical Center
-
Kontakt:
- Sarah Rinehart, MD
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Provided electronic or written informed consent
-
Men > 55, women > 65 years of age
-
Type 2 diabetes mellitus requiring pharmacologic therapy, prediabetes (most recent HbA1c 5.7 to 6.4% and/or fasting glucose 100-125 mg/dL [5.6-6.9 mmol/L]) and/or metabolic syndrome. Metabolic syndrome is defined as > 3 of the following criteria (International Diabetes Federation 2006):
- Body mass index ≥ 27 kg/m2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)
- Fasting triglycerides ≥ 150 mg/dL (1.7 mmol/L) or treated hypertriglyceridemia
- HDL-cholesterol (HDL-C) < 40 mg/dL (1.03 mmol/L) in men, <50 mg/dL (1.29 mmol/L) in women or treatment for this lipid abnormality
- Systolic blood pressure (BP) ≥ 130 and/or diastolic BP≥ 85 mm Hg and/or treated hypertension
- Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or HbA1c ≥ 5.7%
-
Have a device (e.g., smartphone, tablet, computer) for communication with the central cardiologist-led team managing drug treatment for the personalized care group
Exclusion Criteria:
-
History of symptomatic CVD defined as prior MI, exertional or unstable angina, ischemic stroke, claudication, arterial revascularization for atherosclerosis or other CVD being actively managed by a cardiologist, e.g. atrial fibrillation, heart failure
-
Planned arterial revascularization
-
Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:
- eGFR < 60 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org/professionals/kdoqi/gfr_calculator)
- Allergy to iodinated contrast or history of contrast-induced nephropathy (including adverse reaction to contrast at screening CCTA) or screening laboratory values consistent with untreated hyperthyroidism. Participants with elevated thyroid-stimulating hormone (TSH) may be enrolled but should be referred to their physician for evaluation for treatment.
- Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment
- Weight > 300 lbs. (136 kg) or above manufacturer-recommended limit for scanner and table at the site
- Inability to hold breath for > 10 seconds
- Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., > 80 beats per minute at screening or prior to CCTA)
- Contraindication to dosing with beta blocker or nitroglycerin on day of screening CCTA
- Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA
-
Unsuitable as a trial participant in the opinion of the investigator for reasons including significant left main stenosis (e.g. ≥ 70%; site will be notified by Cleerly), other health condition with life expectancy < 3 years or being at risk of poor compliance with study procedures (e.g., active substance abuse or untreated mental illness that, in the opinion of the investigator, is likely to adversely affect adherence or retention)
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Žádný zásah: Risk Factor-Based Care
The risk factor-based care group will be managed by their usual care providers, with an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. During the trial, the centralized cardiology team will monitor the provision of medications prescribed and lab values relative to guidelines, and provide feedback and education to site investigators to support optimization. CCTA results will be centrally archived and will remain blinded to the usual care provider until the end of the study. |
|
|
Experimentální: Cleerly Stage-Based Care
The Cleerly Stage-Based Care group will receive personalized care centrally managed by a remote cardiologist-led team. They will also receive an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. Cleerly CAD Staging System results will be discussed with participants and serve as the basis for standardized algorithm-supported pharmacotherapy & education, which will be intensified if plaque burden has progressed at 24 months. |
The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events.
Časové okno: Through study completion- an average of 3.5 years
|
The primary endpoint is total (first and subsequent) events for the composite endpoint of CV death, myocardial infarction (MI), ischemic stroke, acute limb ischemia, clinically driven arterial revascularization, and hospitalization or urgent visit for heart failure. |
Through study completion- an average of 3.5 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Časové okno: Through study completion- an average of 3.5 years
|
The secondary endpoints are time from randomization to first occurence of an event in the primary efficacy endpoint. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Časové okno: Through study completion- an average of 3.5 years
|
The secondary endpoints are total occurences after randomization of the primary efficacy endpoing, kidney failure, sustained estimated glomerular filtration rate (eGFR) decrease >40% from baseline, and death from renal causes. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Časové okno: Through study completion- an average of 3.5 years
|
The secondary endpoints are first and total occurrences after randomization of coronary death, MI, and urgent coronary revascularization. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Časové okno: Through study completion- an average of 3.5 years
|
The secondary endpoints are time from randomization to first occurrence of MI or ischemic stroke. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Časové okno: Through study completion- an average of 3.5 years
|
The secondary endpoints are time from randomization to all-cause death. |
Through study completion- an average of 3.5 years
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The safety objective is to assess harm with the 2 prevention strategies
Časové okno: Through study completion- an average of 3.5 years
|
The safety endpoints are Adverse events (AE) leading to discontinuation of study-recommended medication (DAE), serious AE (SAE), adverse device effect (ADE). |
Through study completion- an average of 3.5 years
|
|
The safety objective is to assess harm with the 2 prevention strategies
Časové okno: Through study completion- an average of 3.5 years
|
The safety endpoints are 20-item Short Form survey (SF-20). |
Through study completion- an average of 3.5 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Studijní židle: Deepak Bhatt, MD, MPH, Mt. Sinai Heart
- Studijní židle: David J. Maron, MD, FASPC, Stanford University
Publikace a užitečné odkazy
Obecné publikace
- Clerc OF, Fuchs TA, Stehli J, Benz DC, Grani C, Messerli M, Giannopoulos AA, Buechel RR, Luscher TF, Pazhenkottil AP, Kaufmann PA, Gaemperli O. Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Imaging. 2018 Aug 1;19(8):838-846. doi: 10.1093/ehjci/jey014.
- Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM, Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME, Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroeder EB, Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang NY, Yaffe K, Martin SS. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022 Feb 22;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052. Epub 2022 Jan 26.
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 202302CPC
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .